2023-09-08T10:56:10-05:00 2022-10-17 841158905 CAUSEY DEMGEN & MOORE PC 1099 18TH ST STE 2300 DENVER CO 802021939 990 2022-01-01 843360404 INTERNATIONAL LUNG CANCER FOUNDATION INTE 7203252948 999 17TH ST 200 DENVER CO 802022725 JOHN SKADOW CFO 7203252948 2023-09-08 1 JOHN SKADOW 999009999 1 LAUREN J STOLZ P01432391 3032962229 2023-09-08 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z X JOHN SKADOW 999 17TH ST SUITE 200 DENVER CO 80202 4273165 0 X WWW.IASLC.ORG/INTERNATIONAL-LUNG-CANCER-FOUNDATIO X 2019 CO THE INTERNATIONAL LUNG CANCER FOUNDATION AIMS TO ACCELERATE THE PACE OF THORACIC MALIGNANCY RESEARCH, TO INSPIRE RESEARCHERS TO FOCUS THEIR CAREERS ON LUNG CANCER, AND TO REDUCE THE WORLDWIDE LUNG CANCER MORTALITY RATE.DONATIONS FROM PATIENTS, CAREGIVERS, AND THOSE INDIVIDUALS PASSIONATE ABOUT ACCELERATING THE PACE OF LUNG CANCER RESEARCH, AS WELL AS FROM OUR ORGANIZATION AND CORPORATE PARTNERS, GO DIRECTLY TO FUNDING OUR RESEARCH GRANTS. THESE RESEARCH GRANTS PROVIDE EARLY-CAREER RESEARCHERS WITH VITAL FUNDING OPPORTUNITIES, FOSTERING BOTH TOMORROW'S LUNG CANCER VISIONARIES AND MILESTONES IN PATIENT CARE. X 4 4 0 0 0 0 467860 897672 0 0 0 0 0 3375493 467860 4273165 886972 1367599 0 0 152578 94918 0 0 0 79460 60577 1119010 1523094 -651150 2750071 840218 0 3590289 0 -2750071 0 X THE INTERNATIONAL LUNG CANCER FOUNDATION AIMS TO ACCELERATE THE PACE OF THORACIC MALIGNANCY RESEARCH, TO INSPIRE RESEARCHERS TO FOCUS THEIR CAREERS ON LUNG CANCER, AND TO REDUCE THE WORLDWIDE LUNG CANCER MORTALITY RATE.DONATIONS FROM PATIENTS, CAREGIVERS, AND THOSE INDIVIDUALS PASSIONATE ABOUT ACCELERATING THE PACE OF LUNG CANCER RESEARCH, AS WELL AS FROM OUR ORGANIZATION AND CORPORATE PARTNERS, GO DIRECTLY TO FUNDING OUR RESEARCH GRANTS. 0 1 1523094 1367599 3375493 FELLOWSHIPS - PROVIDED TO TRAIN NEXT GENERATION OF LUNG CANCER SPECIALISTS. FUNDING FOR IASLC FELLOWSHIP AND YOUNG INVESTIGATOR AWARDS PROVIDES FOR TRAINING OF FELLOWS AND YOUNG INVESTIGATORS WHO WISH TO PURSUE A CAREER IN DIAGNOSIS, TREATMENT, LABORATORY RESEARCH OR OTHER ASPECTS OF THORACIC MALIGNANCIES. 1523094 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 4 4 0 0 0 0 1 0 0 1 1 0 0 1 1 0 0 1 0 0 0 0 X JOHN SKADOW CFO 7203252948 999 17TH ST SUITE 200 DENVER CO 802022725 DAVID PAUL CARBONE PRESIDENT 1.00 X X 0 0 0 LAUREN FISHER VICE CHAIR 1.00 X X 0 0 0 DAVID R GANDARA TREASURER/SECRETARY 1.00 X X 0 0 0 TETSUYA MITSUDOMI PAST PRESIDENT 1.00 X X 0 0 0 JOHN SKADOW CFO 1.00 X 0 207401 46232 KELLY L KAREN CEO 1.00 X 0 332435 37118 0 539836 83350 0 0 1 0 0 897672 897672 3375493 3375493 3375493 4273165 3375493 0 0 517599 517599 850000 850000 81019 81019 7809 7809 6090 6090 9920 9920 24342 24342 2025 2025 1706 1706 6126 6126 8672 8672 7631 7631 155 155 1523094 1523094 0 0 298892 0 0 510076 0 0 0 0 0 0 31250 0 0 0 0 0 0 0 840218 0 2679861 0 910428 0 3590289 0 X -2750071 0 -2750071 0 840218 0 2750071 0 X X 0 1 X 1 0 X 412984 467860 897672 1778516 412984 467860 897672 1778516 1778516 1778516 1.00000 1.00000 X 0 X PART X, LINE 2: THE FOUNDATION HAS RECEIVED A DETERMINATION FROM THE INTERNAL REVENUE SERVICE (IRS) TO BE EXEMPT FROM FEDERAL INCOME TAXES UNDER THE PROVISION OF INTERNAL REVENUE CODE SECTION 501(C)(3). ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE. THE ASSOCIATION HAS ADOPTED GUIDANCE ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. AFTER EVALUATING THE TAX POSITIONS TAKEN, NONE ARE CONSIDERED TO BE UNCERTAIN; THEREFORE, NO AMOUNTS HAVE BEEN RECOGNIZED AS OF DECEMBER 31, 2021 AND 2020. 0 0 0 0 0 0 0 0 0 0 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 25000 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 75000 0 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 EAST ASIA AND THE PACIFIC SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 SOUTH AMERICA SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 75000 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 NORTH AMERICA SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 100000 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 EUROPE (INCLUDING ICELAND & GREENLAND) SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 50000 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY. 50000 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 25000 0 0 0 0 0 0 0 PART I, LINE 2: 1. GRANTS WILL BE INITIALLY REVIEWED BY THE COMMITTEE CHAIR FOR COMPLETENESS. INCOMPLETE SUBMISSIONS OR GRANTS SUBMITTED AFTER THE DEADLINE WILL BE RETURNED TO THE PI IN 48 HOURS. 2. EACH MEMBER OF THE SCIENTIFIC REVIEW COMMITTEE WILL RIGOROUSLY REVIEW THE APPLICATIONS. APPLICATIONS WILL BE SCORED ON FOUR CRITERIA: A. POTENTIAL OF THE CANDIDATE: IS THE CANDIDATE COMMITTED TO A CAREER IN LUNG CANCER RESEARCH? DOES THE CANDIDATE HAVE BASIC TRAINING RELATED TO THE PROJECT PROPOSED? PUBLISHED/SUBMITTED PAPERS OR ABSTRACTS CURRENT OR PENDING GRANT SUBMISSIONS STRONG LETTERS OF SUPPORT B. SCIENTIFIC MERIT OF THE PROJECT: IS THE PROPOSAL ORIGINAL? IS THE PROPOSAL CLEAR & CONCISE? ARE THE SPECIFIC AIMS REASONABLE? IS THE METHODOLOGY REASONABLE TO ACCOMPLISH THE OBJECTIVES? CAN THE PROJECT BY COMPLETED IN THE 2 YEAR TIME FRAME? C. SIGNIFICANCE OF PROJECT: IS THE PROJECT WITHIN THE IASLC SCOPE? WHAT WILL THIS INFORMATION CONTRIBUTE TO KNOWLEDGE IN THIS FIELD? DO THESE RESULTS SIGNIFICANTLY IMPROVE THE APPLICATION OF KNOWLEDGE OF LUNG CANCER? WILL THESE DATA STIMULATE FURTHER SCIENTIFIC RESEARCH INTO LUNG CANCER? D. STRENGTH OF THE PI/INSTITUTIONAL SUPPORT (FOR FELLOWSHIP GRANTS): IS THE PI DEDICATED TO ASSISTING IN THE EXECUTION AND COMPLETION OF THE PROJECT? IS THE PI OF GOOD STANDING IN THE FIELD OF LUNG CANCER RESEARCH? DOES THE PI HAVE SUFFICIENT GRANT SUPPORT FOR THE FELLOW TO COMPLETE THE PROJECT IF REQUIRED? DOES THE INSTITUTION HAVE THE NECESSARY RESOURCES TO SUPPORT THE PROJECT? SCORES WILL RANGE FROM 1-5. 5 - OUTSTANDING 4 - EXCELLENT 3 - GOOD 2 - POOR 1 - UNACCEPTABLE TOTAL SCORES WILL THEN BE TABULATED, AVERAGED, AND THE CANDIDATE RANKED. THE COMMITTEE WILL MEET BY CONFERENCE CALL TO SELECT THE AWARDEES. 3. PROGRESS REPORTS FROM YEAR 1 WILL BE REVIEWED BY THE COMMITTEE CHAIR. PART III ACCOUNTING METHOD: 0 DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 50000 0 SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY. LUNG CANCER FOUNDATION OF AMERICAN 15 S FRANKLIN ST NEW ULM MN 56073 208730839 501(C)(3) 287500 0 SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY. BOSTON UNIVERSITY 233 BAY STATE ROAD BOSTON MA 02215 042103547 501(C)(3) 50000 0 SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE MANHATTAN NY 10065 131924236 501(C)(3) 25000 0 SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY SIDNEY KIMMEL CANCER CENTER 233 S 10TH ST PHILADELPHIA PA 19107 330148739 501(C)(3) 50000 0 SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY YALE UNIVERSITY 157 CHURCH STREET NEW HAVEN CT 06510 060646973 501(C)(3) 50000 0 SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THORACIC ONCOLOGY 6 PART I, LINE 2: GRANTS WILL BE INITIALLY REVIEWED BY THE COMMITTEE CHAIR FOR COMPLETENESS. INCOMPLETE SUBMISSIONS OR GRANTS SUBMITTED AFTER THE DEADLINE WILL BE RETURNED TO THE PI IN 48 HOURS. 2. EACH MEMBER OF THE SCIENTIFIC REVIEW COMMITTEE WILL RIGOROUSLY REVIEW THE APPLICATIONS. APPLICATIONS WILL BE SCORED ON FOUR CRITERIA: A. POTENTIAL OF THE CANDIDATE: IS THE CANDIDATE COMMITTED TO A CAREER IN LUNG CANCER RESEARCH? DOES THE CANDIDATE HAVE BASIC TRAINING RELATED TO THE PROJECT PROPOSED? PUBLISHED/SUBMITTED PAPERS OR ABSTRACTS CURRENT OR PENDING GRANT SUBMISSIONS STRONG LETTERS OF SUPPORT B. SCIENTIFIC MERIT OF THE PROJECT: IS THE PROPOSAL ORIGINAL? IS THE PROPOSAL CLEAR & CONCISE? ARE THE SPECIFIC AIMS REASONABLE? IS THE METHODOLOGY REASONABLE TO ACCOMPLISH THE OBJECTIVES? CAN THE PROJECT BY COMPLETED IN THE 2 YEAR TIME FRAME? C. SIGNIFICANCE OF PROJECT: IS THE PROJECT WITHIN THE IASLC SCOPE? WHAT WILL THIS INFORMATION CONTRIBUTE TO KNOWLEDGE IN THIS FIELD? DO THESE RESULTS SIGNIFICANTLY IMPROVE THE APPLICATION OF KNOWLEDGE OF LUNG CANCER? WILL THESE DATA STIMULATE FURTHER SCIENTIFIC RESEARCH INTO LUNG CANCER? D. STRENGTH OF THE PI/INSTITUTIONAL SUPPORT (FOR FELLOWSHIP GRANTS): IS THE PI DEDICATED TO ASSISTING IN THE EXECUTION AND COMPLETION OF THE PROJECT? IS THE PI OF GOOD STANDING IN THE FIELD OF LUNG CANCER RESEARCH? DOES THE PI HAVE SUFFICIENT GRANT SUPPORT FOR THE FELLOW TO COMPLETE THE PROJECT IF REQUIRED? DOES THE INSTITUTION HAVE THE NECESSARY RESOURCES TO SUPPORT THE PROJECT? SCORES WILL RANGE FROM 1-5. 5 - OUTSTANDING 4 - EXCELLENT 3 - GOOD 2 - POOR 1 - UNACCEPTABLE TOTAL SCORES WILL THEN BE TABULATED, AVERAGED, AND THE CANDIDATE RANKED. THE COMMITTEE WILL MEET BY CONFERENCE CALL TO SELECT THE AWARDEES. 3. PROGRESS REPORTS FROM YEAR 1 WILL BE REVIEWED BY THE COMMITTEE CHAIR. 0 0 0 0 0 0 0 0 0 KELLY L KAREN CEO 0 332435 0 0 0 0 0 28940 0 8178 0 369553 0 0 JOHN SKADOW CFO 0 199401 0 8000 0 0 0 20536 0 25696 0 253633 0 0 PART I, LINE 3 OFFICERS MAY RECEIVE REASONABLE COMPENSATION FOR SERVING IN SUCH OFFICE. THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER SHALL REIMBURSE ANY OFFICER FOR ALL REASONABLE EXPENSES INCURRED BY SUCH INDIVIDUAL IN CONNECTION WITH SERVICES RENDERED TO OR FOR THE ASSOCIATION AND ITS FOUNDATION. UNRESTRICTED NET ASSETS 2022-10-17 3375493 BOOK 200499338 INTERNATIONAL ASSOCIATION FOR STUDY OF LUNG CANCER 999 17TH STREET SUITE 200 DENVER CO 80202 501(C)(3) 0 0 0 0 1 1 1 1 0 FORM 990, PART III, LINE 3 A BOARD DECISION WAS MADE TO DISCONTINUE OPERATIONS OF THE INTERNATIONAL LUNG CANCER FOUNDATION AS IT WAS NO LONGER SUSTAINABLE. ALL ASSETS WERE TRANSFERRED TO THE RELATED ORGANIZATION - INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER. FORM 990, PART VI, SECTION A, LINE 6 THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, A COLORADO NONPROFIT CORPORATION, SHALL BE THE SOLE MEMBER OF THE FOUNDATION. FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO FILING THE RETURN PREPARER SUBMITS A COPY OF THE TAX RETURN TO THE CEO AND CFO WHO REVIEWS AND SIGN FORM 990. THE BOARD WILL REVIEW THE TAX RETURNS FOLLOWING THE FILING OF THE FORM 990. FORM 990, PART VI, SECTION C, LINE 19 THE FORMS ARE AVILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C PRIOR TO FILING THE RETURN PREPARER SUBMITS A COPY OF THE TAX RETURN TO THE TREASURER WHO REVIEWS AND SIGNS FORM 990. INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER 999 17TH STREET SUITE 200 DENVER CO 802022725 200499338 CANCER RESEARCH CO 501(C)(3) LINE 10 N/A 0 IASLC FOUNDATION 999 17TH STREET SUITE 200 DENVER CO 802022725 464169885 CANCER RESEARCH CO 501(C)(3) LINE 12A, I INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER N 8672 ALLOCATION OF SQUARE FOOTAGE/TIME INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER O 94919 ALLOCATION OF HOURLY WAGES